- Home
- SILO vs CHRO Comparison
SILO vs CHRO Comparison
Compare SILO & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILO
- CHRO
- Stock Information
- Founded
- SILO 2010
- CHRO 2002
- Country
- SILO United States
- CHRO United States
- Employees
- SILO N/A
- CHRO N/A
- Industry
- SILO Apparel
- CHRO
- Sector
- SILO Consumer Discretionary
- CHRO
- Exchange
- SILO Nasdaq
- CHRO Nasdaq
- Market Cap
- SILO 8.8M
- CHRO 8.1M
- IPO Year
- SILO N/A
- CHRO 2024
- Fundamental
- Price
- SILO $1.16
- CHRO $1.35
- Analyst Decision
- SILO
- CHRO Strong Buy
- Analyst Count
- SILO 0
- CHRO 1
- Target Price
- SILO N/A
- CHRO N/A
- AVG Volume (30 Days)
- SILO 92.8K
- CHRO 2.0M
- Earning Date
- SILO 05-12-2025
- CHRO 05-14-2025
- Dividend Yield
- SILO N/A
- CHRO N/A
- EPS Growth
- SILO N/A
- CHRO N/A
- EPS
- SILO N/A
- CHRO N/A
- Revenue
- SILO $72,102.00
- CHRO N/A
- Revenue This Year
- SILO $1.86
- CHRO N/A
- Revenue Next Year
- SILO N/A
- CHRO N/A
- P/E Ratio
- SILO N/A
- CHRO N/A
- Revenue Growth
- SILO N/A
- CHRO N/A
- 52 Week Low
- SILO $0.77
- CHRO $0.45
- 52 Week High
- SILO $4.50
- CHRO $3.80
- Technical
- Relative Strength Index (RSI)
- SILO 47.25
- CHRO 46.67
- Support Level
- SILO $0.99
- CHRO $1.29
- Resistance Level
- SILO $1.19
- CHRO $1.65
- Average True Range (ATR)
- SILO 0.08
- CHRO 0.19
- MACD
- SILO 0.02
- CHRO 0.02
- Stochastic Oscillator
- SILO 75.00
- CHRO 13.79
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.